What is Eiger BioPharmaceuticals Inventory-to-Revenue?
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Eiger BioPharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2023 was $1.33 Mil. Eiger BioPharmaceuticals's Revenue for the
three
months ended in Dec. 2023 was $3.80 Mil.
Eiger BioPharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.35.
Eiger BioPharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023
increased
from Sep. 2023 (0.34) to Sep. 2023 (0.35)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Eiger BioPharmaceuticals's Days Inventory for the
three
months ended in Dec. 2023 was 1,202.06.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Eiger BioPharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.08.
Eiger BioPharmaceuticals Inventory-to-Revenue Historical Data
The historical data trend for Eiger BioPharmaceuticals's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Eiger BioPharmaceuticals's Inventory-to-Revenue
For the Biotechnology subindustry, Eiger BioPharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiger BioPharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Eiger BioPharmaceuticals's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Eiger BioPharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Eiger BioPharmaceuticals's Days Inventory for the
three
months ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eiger BioPharmaceuticals Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EIGRQ has been successfully added to your 